ArticleLife (Basel, Switzerland)2021
A New Classification of the Severity of Psoriasis: What's Moderate Psoriasis?
Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.Scientific reports · 2025Trial
- Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study.Advances in therapy · 2025Trial
- Modified Delphi Consensus Recommendations for the Management of Psoriasis in Asia-Pacific.Dermatology and therapy · 2026Article
- Psoriasis Is Accompanied by Low Serum Levels of MG-H1, GOLD and MOLD: LC-Orbitrap-MS/MS Analysis of Chosen Glycation Products.Molecules (Basel, Switzerland) · 2026Article
- Epidemiological Profile of Psoriasis and Linked Comorbidities in Chinese Population at Shenzhen: A Cross-Sectional Study.Health science reports · 2025Article
- A Common Genetic Background for Psoriasis and Cardiovascular Diseases: A Narrative Review.Health science reports · 2025Article
- Exploring the Therapeutic Potential of Lipid Nanocarriers in Psoriasis Management: Advances and Applications.AAPS PharmSciTech · 2025Review
- Best Responders and Super-Responders to Calcipotriol and Betamethasone Dipropionate PAD-Cream: A Post Hoc Pooled Analysis of Two Phase 3 Trials.Dermatology and therapy · 2025Article
- A Promising Approach to Psoriasis Vulgaris Management with N-Acetylcysteine and Vitamin E: Targeting the Interplay of Inflammatory and Oxidative Stress.Biomedicines · 2025Article
- Low Serum Methylglyoxal Levels Correlate with Psoriasis Severity and Inflammatory Response Indices.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Article
- Therapeutic Advancements in the Management of Psoriasis: A Clinical Overview and Update.Cureus · 2025Review
- Psoriasis severity classification based on adaptive multi-scale features for multi-severity disease.Scientific reports · 2023Article
- Prevalence of Non-Alcoholic Fatty Liver Disease in Adult Individuals with Moderate-to-Severe Atopic Dermatitis.Journal of clinical medicine · 2023Article
- Challenges and Future Trends in the Treatment of Psoriasis.International journal of molecular sciences · 2023Review
- Insights into Nutritional Strategies in Psoriasis.Nutrients · 2023Review
- Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria - results the APPRECIATE study.Therapeutic advances in chronic disease · 2023Article
- Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness.Life (Basel, Switzerland) · 2022Review
- Antiproliferative and Anti-Inflammatory Activities of Deprungsith Formulation and Its Bioactive Compounds Against Mild Psoriasis and Potential of Metabolic Herb-Drug Interactions.Journal of evidence-based integrative medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The purpose of this study is to propose a ranking system for the severity of psoriasis. The consensus method of selecting the indices to include and the classification of real patient profiles by an expert panel to create a gold standard of severity were used. The performance of potential cut-offs was evaluated to create a ranking algorithm. The combined use of PASI, BSA, and sPGA may allow the classification of the severity of psoriatic patients. The final algorithm identifies severe patients in a single step (2 out 3 are met: PASI ≥ 11 or BSA ≥ 10 or sPGA ≥ 3), while two steps are required for mild ((2 out 3 are met: PASI ≤ 3 or BSA ≤ 5 or sPGA ≤ 2) and DLQI < 5) and moderate forms (the patient does not meet 2 out 3 (PASI ≥ 11 or BSA ≥ 10 or sPGA ≥ 3) but has a DLQI ≥ 5. A ranking algorithm is presented, consisting of different measures of disease which classifies psoriatic patients into three categories: mild, moderate, and severe.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.